Liopo A, Conjusteau A, Konopleva M, Andreeff M, Oraevsky A
Nano Biomed Eng. 2012; 4(2):66-75.
PMID: 22720194
PMC: 3377581.
DOI: 10.5101/nbe.v4i2.p66-75.
Small G, Strum J, Daniel L
Lipids. 1997; 32(7):715-23.
PMID: 9252959
DOI: 10.1007/s11745-997-0091-3.
Diomede L, Piovani B, MODEST E, Salmona M
Lipids. 1993; 28(3):189-92.
PMID: 8464349
DOI: 10.1007/BF02536638.
Brunton V, Workman P
Br J Cancer. 1993; 67(5):989-95.
PMID: 8388233
PMC: 1968438.
DOI: 10.1038/bjc.1993.181.
Berdel W
Blut. 1982; 44(2):71-8.
PMID: 7059692
DOI: 10.1007/BF00320092.
Response of acute myelomonocytic leukemia to alkyl-lysophospholipids. A case report.
Berdel W, Fink U, Maubach P, Permanetter B, Rastetter J
Blut. 1982; 44(3):177-86.
PMID: 6952952
DOI: 10.1007/BF00320765.
Cytotoxic activity in the serum of a patient with metastasizing nephroblastoma given intravenous infusions of alkyl-lysophospholipids in a phase I study.
Andreesen R, Arnold H, LOHR G
Blut. 1982; 44(2):79-82.
PMID: 6277413
DOI: 10.1007/BF00320093.
Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.
Dulisch I, Neumann H, LOHR G, Andreesen R
Blut. 1985; 51(6):393-9.
PMID: 3865693
DOI: 10.1007/BF00320725.
Ether lipid derivatives: antineoplastic activity in vitro and the structure-activity relationship.
Berdel W, Von Hoff D, Unger C, Schick H, Fink U, Reichert A
Lipids. 1986; 21(4):301-4.
PMID: 3713449
DOI: 10.1007/BF02536417.
Immunomodulatory and therapeutic properties of alkyl lysophospholipids in mice.
Talmadge J, Schneider M, Lenz B, Phillips H, Long C
Lipids. 1987; 22(11):871-7.
PMID: 3502167
DOI: 10.1007/BF02535547.
In vitro and in vivo cytotoxicity of alkyl lysophospholipid ET-18-OCH3 and thioether lipid BM 41.440.
Leder G, Fiebig H, Wallbrecher E, Winterhalter B, LOHR G
Lipids. 1987; 22(11):958-61.
PMID: 3444393
DOI: 10.1007/BF02535564.
Cytotoxic activity of the thioether phospholipid analogue BM 41.440 in primary human tumor cultures.
Herrmann D, Neumann H
Lipids. 1987; 22(11):955-7.
PMID: 3444392
DOI: 10.1007/BF02535563.
Antineoplastic activity of the thioether lysophospholipid derivative BM 41.440 in vitro.
Fromm M, Berdel W, Schick H, Fink U, Pahlke W, Bicker U
Lipids. 1987; 22(11):916-8.
PMID: 3444385
DOI: 10.1007/BF02535554.
Structure-cytotoxicity studies on alkyl lysophospholipids and some analogs in leukemic blasts of human origin in vitro.
Danhauser S, Berdel W, Schick H, Fromm M, Reichert A, Fink U
Lipids. 1987; 22(11):911-5.
PMID: 3444384
DOI: 10.1007/BF02535553.
Neoplastic cell inhibition with new ether lipid analogs.
Noseda A, Berens M, Piantadosi C, MODEST E
Lipids. 1987; 22(11):878-83.
PMID: 3444381
DOI: 10.1007/BF02535548.
Metabolism of ether phospholipids and analogs in neoplastic cells.
Fleer E, Unger C, Kim D, Eibl H
Lipids. 1987; 22(11):856-61.
PMID: 3444378
DOI: 10.1007/BF02535544.
Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients.
Herrmann D, Neumann H, Berdel W, Heim M, Fromm M, Boerner D
Lipids. 1987; 22(11):962-6.
PMID: 3328028
DOI: 10.1007/BF02535565.
Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation.
VOGLER W, Olson A, Okamoto S, Somberg L, Glasser L
Lipids. 1987; 22(11):919-24.
PMID: 3328027
DOI: 10.1007/BF02535555.
The chemotherapeutic potential of glycol alkyl ethers: structure-activity studies of nine compounds in a Fischer-rat leukemia transplant model.
Dieter M, Jameson C, Maronpot R, Langenbach R, Braun A
Cancer Chemother Pharmacol. 1990; 26(3):173-80.
PMID: 2357763
DOI: 10.1007/BF02897195.
Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.
Himmelmann A, Steinhauser G, Busch R, MODEST E, Noseda A, Rastetter J
Cancer Chemother Pharmacol. 1990; 26(6):437-43.
PMID: 2225315
DOI: 10.1007/BF02994095.